Biotech Stock Boosted on Brand-New 'Buy' Rating

Core Viewpoint - Merus NV (NASDAQ:MRUS) has seen a positive market reaction following Goldman Sachs' initiation of coverage with a "buy" rating, driven by the potential growth from its cancer treatment [1]. Group 1: Stock Performance - MRUS stock is currently up 3.4% at $44.40, recovering from a recent decline and aiming to end an eight-day losing streak [1][2]. - The stock dropped below its long-term support at the 200-day moving average, which was at$42, coinciding with a pre-bull gap level from April [2]. - Year-to-date, MRUS has increased by 58.3% [2]. Group 2: Analyst Ratings - All 17 analysts covering Merus stock have a "buy" or better rating, indicating strong bullish sentiment [2]. - The 12-month consensus price target for MRUS is $86.60, representing a 98.4% premium to current levels [2]. Group 3: Options Market Sentiment - Options traders are optimistic, with a 50-day call/put volume ratio of 6.88, ranking in the 93rd percentile of its annual range [3].